U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition

Size: px
Start display at page:

Download "U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition"

Transcription

1 U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition CFSAN Adverse Event Reporting System Voluntary and Mandatory Reports on 5-Hour Energy, Monster Energy, and Rockstar Energy Drink January 1, 2004, through October 23, 2012 Introduction FDA s Center for Food Safety and Applied Nutrition (CFSAN) Adverse Event Reporting System (CAERS) collects reports about adverse health events and product complaints related to CFSAN-regulated products, including conventional foods, dietary supplements, and cosmetics. Based on a search of CAERS, this document summarizes the adverse events reported to FDA in connection with products under the labels 5-Hour Energy, Monster, and Rockstar between January 1, 2004 and October 23, These products are currently marketed as dietary supplements. CAERS includes voluntary reports for cosmetics and conventional foods, and both voluntary and mandatory reports for dietary supplements. Mandatory reports are those required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act. Specifically, dietary supplement manufacturers, packers, and distributors must notify FDA if they receive reports about serious adverse events in connection with the use of their products. This law defines a serious adverse event as an adverse health-related event that is associated with the use of a dietary supplement and that results in death, a lifethreatening experience, inpatient hospitalization, a persistent or significant disability or incapacity, a congenital anomaly or birth defect, or that requires, based on reasonable medical judgment, a medical or surgical intervention to prevent one of those outcomes. The requirement to report serious adverse events to FDA applies only to dietary supplements and not to beverages, other conventional foods, or cosmetics. Medical officers with the agency's Dietary Supplement Program staff review all serious adverse events reported to FDA about dietary supplements as part of the normal process of assessment and categorization. In addition to these mandatory reports, the CAERS system also contains adverse events (both serious and non-serious) that are voluntarily reported to FDA by consumers and health care providers. FDA encourages consumers and health care providers to report adverse events they believe may be related to FDA-regulated products to FDA's MedWatch Adverse Event Reporting Program ( FDA advises consumers to talk with their health care providers before using any product marketed as an energy shot or energy drink.

2 Things You Should Know About Adverse Event Report Data Individual adverse event reports about a particular product and the total number of adverse event reports for that product in CAERS only reflect information AS REPORTED and do not represent any conclusion by FDA about whether the product actually caused the adverse events. Because CAERS is constantly updated with new information, the number of reports for a given product and the content of individual reports may change over time. Even with mandatory reporting of serious adverse events for dietary supplements, generally only a small fraction of adverse events associated with any product is reported. On the other hand, there may be duplicate reports in CAERS for the same adverse event because multiple people (such as an injured consumer and a health care provider who treated him or her) may have submitted reports. There are important limitations to making inferences based on data from adverse event reports, such as those in CAERS. Reports to FDA do not necessarily include all relevant data, such as whether an individual also suffered from other medical conditions (such as cardiac disease) or took other supplements or medication at the same time. Reports may not include accurate or complete contact information for FDA to seek further information about the event, or complainants may choose not to participate in the follow-up investigation. When important information is missing from a report, it is difficult for FDA to fully evaluate whether the product caused the adverse event or simply coincided with it. The fact that an adverse event happened after a person took a dietary supplement does not necessarily mean that the dietary supplement caused the adverse event.

3 CAERS Adverse Events Reports Allegedly Related to 5 Hour Energy Search Terms: 5 Hour, Five Hour, 5Hour, FiveHour The Center for Food Safety Adverse Event Reporting System (CAERS) is a post-market surveillance system that collects reports about events or problems that are allegedly related to CFSAN regulated products. In some reports, information in the reports cannot be verified for accuracy. Furthermore, in many reports, individuals may have used other products, and many products contain multiple ingredients which further complicates the evaluation of adverse event reports. There is no certainty that a reported adverse event can be attributed to a particular product or ingredient. The number of adverse event reports in CAERS received by FDA and the adverse event report itself about a particular product only reflects information AS REPORTED and does not represent any conclusion by FDA regarding a causal relationship or association with the product or ingredient. Due to the continuous inclusion of new or updated information into the CAERS system, reports released from CAERS containing adverse event data may change over time. Each report received by CAERS regarding an individual that experiences an adverse event is assigned a unique report number (Report #). ^ Additional dates indicate receipt of additional materials on report. Report # Brand/ Product /22/05 5 HOUR ENERGY CHASER FEELING ABNORMAL, FLUSHING 97070^ 5/11/07 LIVING ESSENTIALS 5 HOUR FLAVOR ENERGY FLUSHING, LETHARGY, DIZZINESS, ANXIETY, DYSPNOEA, BLOOD PRESSURE FLUCTUATION, HEART RATE ABNORMAL, DYSPNOEA, SHOCK, CHEST PAIN, SYNCOPE, VOMITING, DIARRHOEA, VISUAL DISTURBANCE, DEAFNESS, MOOD ALTERED, FATIGUE, PALPITATIONS, TACHYCARDIA, HEART RATE INCREASED, DEPRESSION, HEADACHE, ANAPHYLACTIC REACTION LIFE THREATENING, VISITED AN ER, VISITED A HEALTH CARE PROVIDER, REQ. INTERVENTION TO PRVNT PERM. IMPRMNT. 10/19/ /14/07 5 HOUR ENERGY ENERGY - FLAVOR HYPERVENTILATION, DYSPHONIA, DISORIENTATION, TREMOR, DYSPNOEA, CONVULSION, POISONING, LIFE THREATENING, VISITED AN ER, VISITED A HEALTH CARE PROVIDER, SERIOUS INJURIES/ ILLNESS Page 1

4 Brand/ Product ^ 3/10/08 LIVING ESSENTIALS 5 - HOUR ENERGY FLAVORED VITAMIN SUPPLEMENT HEART RATE ABNORMAL, FAECAL INCONTINENCE, LOSS LIFE THREATENING, OF CONSCIOUSNESS, DIZZINESS, VOMITING, DISORIENTATION, AGGRESSION, LOSS OF CONSCIOUSNESS, LETHARGY, HEADACHE, TENDERNESS, DIZZINESS, VOMITING PROJECTILE, HEART RATE INCREASED, DRUG TOXICITY 12/17/ /10/08 LIVING ESSENTIALS 5 - HOUR ENERGY FLAVORED VITAMIN SUPPLEMENT VOMITING, HEART RATE INCREASED /17/08 5 HOUR ENERGY SHOT /23/08 LIVING ESSENTIALS 5 HOUR ENERGY /29/08 INNOVATION VENTURES, LLC 5- HOUR ENERGY HAEMORRHAGE BLOOD PRESSURE FLUCTUATION, LETHARGY, DIZZINESS NERVOUSNESS, NAUSEA, DIZZINESS, LOSS OF CONSCIOUSNESS, HALLUCINATION /5/09 5 HOUR ENERGY ABNORMAL LOSS OF WEIGHT, SLEEP DISORDER, ANXIETY ^ 12/17/09 5 HOUR ENERGY SNEEZING, FALL, VOMITING, CHEST PAIN, PULSE ABSENT, HEAD INJURY 12/30/09 VISITED A HEALTH CARE PROVIDER, DEATH 3/1/ ^ 12/17/09 5 HOUR ENERGY DEATH DEATH 8/3/ /17/09 5 HOUR ENERGY ABORTION SPONTANEOUS OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) Page 2

5 Brand/ Product /29/09 5 HOUR ENERGY DYSPNOEA, CHEST PAIN, SWELLING VISITED AN ER, /16/10 5 HOUR ENERGY FLAVOR HYPERSENSITIVITY VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /16/10 5 HOUR ENERGY MALAISE, HEART RATE INCREASED, HEAT ILLNESS VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /16/10 5 HOUR ENERGY MYOCARDIAL INFARCTION VISITED AN ER, VISITED A HEALTH CARE PROVIDER /16/10 5 HOUR ENERGY HOT FLUSH, HEART RATE INCREASED, ANXIETY, VISUAL IMPAIRMENT /22/10 5 HOUR ENERGY HYPERHIDROSIS, HEART RATE INCREASED, ANXIETY, DIZZINESS, FEAR ^ 4/21/10 5 HOUR ENERGY ARRHYTHMIA, SUPRAVENTRICULAR TACHYCARDIA, PALLOR, ANGINA PECTORIS OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) VISITED AN ER, VISITED A HEALTH CARE PROVIDER 9/29/ /19/10 5 HOUR ENERGY FEAR, MALAISE LIFE THREATENING ^ 5/19/10 5 HOUR ENERGY CONVULSION OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) 3/16/ /14/10 5 HOUR ENERGY PALLOR, CHEST PAIN LIFE THREATENING, VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /14/10 5 HOUR ENERGY CARDIAC ARREST LIFE THREATENING Page 3

6 Brand/ Product /14/10 5 HOUR ENERGY CONVULSION VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /28/10 5 HOUR ENERGY DISORIENTATION, DIZZINESS, HEADACHE, CEREBROVASCULAR ACCIDENT, VISUAL ACUITY REDUCED DISABILITY, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), ^ 7/26/10 5 HOUR ENERGY CONVULSION, SOMNOLENCE 3/16/ /13/10 5 HOUR ENERGY 5 HOUR ENERGY VENTRICULAR ARRHYTHMIA, LOSS OF CONSCIOUSNESS, PNEUMONIA, CONVULSION, ACUTE RESPIRATORY FAILURE, ANOXIC ENCEPHALOPATHY, DEATH /20/10 5 HOUR ENERGY PALPITATIONS, HYPERTENSION /26/10 5 HOUR ENERGY DEATH DEATH /28/10 5 HOUR ENERGY SOMNOLENCE DEATH ^ 10/28/10 5 HOUR ENERGY LEMON LIME DEHYDRATION, PARALYSIS, FEELING JITTERY, TREMOR, MUSCLE CONTRACTIONS INVOLUNTARY, BLOOD POTASSIUM DECREASED, BLOOD CAFFEINE INCREASED VISITED AN ER, LIFE THREATENING 10/28/10 5 HOUR ENERGY EXTRA STRENGTH ^ 10/2/10 5 HOUR ENERGY - CONVULSION, BITE OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) GRAPE 10/2/10 5 HOUR ENERGY - FLAVOR Page 4

7 Brand/ Product /12/10 5-HOUR ENERGY POMEGRANA TE /12/10 5-HOUR ENERGY DYSPHAGIA, JOINT DISLOCATION, PAIN, SWELLING, BRUXISM, JAW DISORDER CONVULSION OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), VISITED AN ER, VISITED A HEALTH CARE PROVIDER /12/10 5 HOUR ENERGY CONVULSION OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /2/10 5-HOUR ENERGY RENAL FAILURE OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /18/10 5 HOUR ENERGY DIETARY SUPPLEMENT ENERGY HEART RATE ABNORMAL, LOSS OF CONSCIOUSNESS, DIZZINESS VISITED A HEALTH CARE PROVIDER /24/11 5-HOUR ENERGY /24/11 5-HOUR ENERGY AURA, LOSS OF CONSCIOUSNESS, CONVULSION CARDIAC ARREST, CEREBROVASCULAR ACCIDENT, DIZZINESS, FEELING JITTERY, RESPIRATORY ARREST VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) DISABILITY, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), LIFE THREATENING, /24/11 5-HOUR ENERGY POMEGRANA TE CONVULSION, PAIN, TREMOR, MUSCLE TWITCHING, VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /25/11 5 HOUR ENERGY ANAPHYLACTIC SHOCK, DYSPNOEA, CHEST PAIN LIFE THREATENING, VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /25/11 5 HOUR ENERGY HYPOAESTHESIA, SUICIDAL IDEATION, PAIN, ACTIVITIES OF DAILY LIVING IMPAIRED OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), ^ 3/8/11 5 HOUR ENERGY HYPOAESTHESIA, BLOOD CREATINE PHOSPHOKINASE MB INCREASED VISITED A HEALTH CARE PROVIDER, 6/27/ /24/11 5 HOUR ENERGY MYOCARDIAL INFARCTION, DEATH DEATH Page 5

8 Brand/ Product /24/11 5 HOUR ENERGY ANAPHYLACTIC SHOCK, URTICARIA, DYSPNOEA, LETHARGY, HYPERSOMNIA, ASTHENIA LIFE THREATENING, VISITED AN ER, VISITED A HEALTH CARE PROVIDER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /21/11 5 HOUR ENERGY EXTRA STRENGTH RENAL IMPAIRMENT, FOETAL DISTRESS SYNDROME LIFE THREATENING, CONGENITAL ANOMALY /13/11 5 HOUR ENERGY DEATH DEATH /13/11 5 HOUR ENERGY DEATH DEATH /13/11 5 HOUR ENERGY EXTRA STRENGTH ACUTE MYOCARDIAL INFARCTION, DIZZINESS, LOSS OF CONSCIOUSNESS, CEREBROVASCULAR ACCIDENT, VISITED AN ER, LIFE THREATENING /13/11 5 HOUR ENERGY HYPOTENSION OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), /13/11 5-HOUR ENERGY/ POMEGRANA TE /27/11 5 HOUR ENERGY ORANGE PAIN, HYPERHIDROSIS, CHEST DISCOMFORT, HEART RATE DECREASED PAIN, GENERALISED ERYTHEMA, HYPERTENSION, FEELING HOT, SWELLING FACE, HYPERSENSITIVITY, DYSPNOEA, URTICARIA, PALPITATIONS, PRURITUS, PO2 DECREASED, BREATH SOUNDS ABSENT, VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) VISITED AN ER, LIFE THREATENING /26/11 5 HOUR ENERGY COMA, CEREBROVASCULAR ACCIDENT, HYPOAESTHESIA, VISUAL IMPAIRMENT, DISABILITY /27/11 5 HOUR ENERGY VOMITING, HAEMATEMESIS, OESOPHAGEAL INJURY, INJURY OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), /1/11 5 HOUR ENERGY LETHARGY, ABDOMINAL PAIN, HEART RATE ABNORMAL /25/11 5 HOUR ENERGY DEATH DEATH Page 6

9 Brand/ Product /25/11 5 HOUR ENERGY ABDOMINAL PAIN UPPER, NAUSEA, PAIN, BODY TEMPERATURE INCREASED, VOMITING, JAUNDICE, HEPATITIS, AMMONIA INCREASED, ALANINE AMINOTRANSFERASE INCREASED, BLOOD BILIRUBIN INCREASED, ASPARTATE AMINOTRANSFERASE INCREASED, BLOOD BILIRUBIN INCREASED, GAMMA- GLUTAMYLTRANSFERASE INCREASED VISITED AN ER, /12/11 5 HOUR ENERGY COLD SWEAT, DIZZINESS, BLOOD PRESSURE DECREASED, LOSS OF CONSCIOUSNESS, CONVULSION, MYOCARDIAL INFARCTION, DYSPNOEA, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), LIFE THREATENING /13/11 LIVING ESSENTIALS/ VOMITING, BURNING SENSATION FLAVORED 5- HOUR ENERGY, VISITED A HEALTH CARE PROVIDER, VISITED AN ER /1/11 5 HOUR ENERGY CEREBROVASCULAR ACCIDENT, CEREBRAL HAEMORRHAGE LIFE THREATENING, /15/11 5 HOUR ENERGY LEMON LIME HYPERSENSITIVITY LIFE THREATENING /15/11 5 HOUR ENERGY POMEGRANA TE HYPERSENSITIVITY VISITED AN ER, LIFE THREATENING /15/11 5-HOUR ENERGY ACQUIRED IMMUNODEFICIENCY SYNDROME OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /24/11 5 HOUR ENERGY MYOCARDIAL INFARCTION DEATH /22/11 LIVING ESSENTIALS 5 HOUR ENERGY POMEGRANA TE ENERGY SHOT ABDOMINAL PAIN, ABDOMINAL PAIN UPPER /30/11 5 HOUR ENERGY HOSPITALISATION Page 7

10 Brand/ Product /30/11 5-HOUR ENERGY DEATH DEATH /6/12 5 HOUR ENERGY MYOCARDIAL INFARCTION OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) ^ 2/6/12 5 HOUR ENERGY ORANGE DYSPNOEA, TREMOR, HYPOAESTHESIA, CHEST PAIN, VISITED AN ER, NON-SERIOUS INJURIES/ ILLNESS 2/6/12 5 HOUR ENERGY POMEGRANA TE /10/12 5 HOUR ENERGY CEREBROVASCULAR ACCIDENT, CARDIOMEGALY, HEART RATE INCREASED OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /14/12 5 HOUR ENERGY VOMITING /2/12 5 HOUR ENERGY /2/12 5 HOUR ENERGY /2/12 5 HOUR ENERGY ^ 3/9/12 5 HOUR ENERGY CONVULSION CONVULSION CONVULSION MYOCARDIAL INFARCTION, CHEST PAIN OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) OTHER SERIOUS (IMPORTANT MEDICAL EVENTS),, VISITED AN ER, VISITED A HEALTH CARE PROVIDER 4/18/ /16/12 5-HOUR ENERGY RENAL DISORDER, JAUNDICE, TONGUE DISCOLOURATION OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), /16/12 5 HOUR ENERGY ANAPHYLACTIC REACTION, DYSPNOEA, URTICARIA, VISITED AN ER, LIFE THREATENING Page 8

11 Brand/ Product /23/12 5 HOUR ENERGY MYOCARDIAL INFARCTION, CIRCULATORY COLLAPSE OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) ^ 4/6/12 5 HOUR ENERGY EXTRA STRENGTH GRAPE FATIGUE, MIGRAINE, DIZZINESS, NAUSEA, AGITATION, DEPENDENCE, MALAISE, DRUG WITHDRAWAL SYNDROME, FEELING ABNORMAL 4/6/12 5 HOUR ENERGY /6/12 5 HOUR ENERGY CONVULSION OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /15/12 FIVE HOUR ENERGY BOOSTER DIARRHOEA, VOMITING, CHROMATURIA, JAUNDICE, PRURITUS, ANOREXIA, BILIARY SPHINCTEROTOMY, CHOLESTASIS, GALLBLADDER DISORDER, PANCREATIC DISORDER OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), /1/12 5 HOUR ENERGY ABDOMINAL PAIN UPPER, VOMITING, BACK PAIN, DIARRHOEA HAEMORRHAGIC, GASTRIC DISORDER, GASTRIC HAEMORRHAGE, VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) ^ 7/19/12 5-HOUR ENERGY POMEGRANA TE LOSS OF CONSCIOUSNESS, HEAD INJURY, DIZZINESS, CONCUSSION, TREMOR, CONVULSION, BRAIN OEDEMA VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) 8/31/ ^ 7/24/12 5-HOUR ENERGY GRAPE ERYTHEMA, PRURITUS, TONGUE OEDEMA, URTICARIA, OBSTRUCTIVE AIRWAYS DISORDER, DYSPHAGIA VISITED AN ER, LIFE THREATENING 10/17/ /7/12 5-HOUR ENERGY COELIAC DISEASE /7/12 5 HOUR ENERGY COMPLETED SUICIDE DEATH Page 9

12 Brand/ Product ^ 9/10/12 5 HOUR ENERGY HOSPITALISATION 9/28/ /10/12 5 HOUR ENERGY FEELING ABNORMAL, SOMNOLENCE, LOSS OF CONSCIOUSNESS, COMA, DRUG TOXICITY, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /10/12 5 HOUR ENERGY HEART RATE IRREGULAR, MYOCARDIAL INFARCTION OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /1/12 5 HOUR ENERGY SUDDEN CARDIAC DEATH, FATIGUE, LOSS OF CONSCIOUSNESS, MYOCARDIAL INFARCTION /28/12 5-HOUR ENERGY METABOLIC ACIDOSIS, SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, BRONCHOSPASM, HEPATIC ENZYME INCREASED, INSOMNIA, MYOGLOBIN BLOOD INCREASED, MANIA DEATH OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /22/12 5-HOUR ENERGY MOTOR DYSFUNCTION, CONVULSION OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) 92 Page 10

13 CAERS Adverse Events Reports Allegedly Related to Monster Search Terms: Monster The Center for Food Safety Adverse Event Reporting System (CAERS) is a post-market surveillance system that collects reports about events or problems that are allegedly related to CFSAN regulated products. In some reports, information in the reports cannot be verified for accuracy. Furthermore, in many reports, individuals may have used other products, and many products contain multiple ingredients which further complicates the evaluation of adverse event reports. There is no certainty that a reported adverse event can be attributed to a particular product or ingredient. The number of adverse event reports in CAERS received by FDA and the adverse event report itself about a particular product only reflects information AS REPORTED and does not represent any conclusion by FDA regarding a causal relationship or association with the product or ingredient. Due to the continuous inclusion of new or updated information into the CAERS system, reports released from CAERS containing adverse event data may change over time. Each report received by CAERS regarding an individual that experiences an adverse event is assigned a unique report number (Report #). *Previous versions of this document may include CAERS reports and Since we received two CAERS reports for the same individual, we have merged them into a single CAERS report (150942). ^ Additional dates indicate receipt of additional materials on report. Report # Brand/Product /4/04 MONSTER ENERGY ABDOMINAL PAIN UPPER, ENERGY SUPPLEMENT RETCHING, VOMITING, DIARRHOEA, WEIGHT DECREASED, DIZZINESS, HOSPITALISATION LIFE THREATENING, /11/04 MONSTER ENERGY MYOCARDIAL INFARCTION, ELECTROCARDIOGRAM ST SEGMENT ELEVATION, HOSPITALISATION, LIFE THREATENING /10/05 MONSTER BEVERAGE FATIGUE CO MONSTER ENERGY VISITED A HEALTH CARE PROVIDER /6/05 HANSENS MONSTER ENERGY PHARYNGITIS, DIZZINESS /22/06 MONSTER ENERGY TREMOR, DYSPNOEA, VOMITING, CHEST PAIN, TREMOR, RHABDOMYOLYSIS, MYOCLONUS, VISITED AN ER, LIFE THREATENING /7/09 MONSTER ENERGY /7/09 MONSTER BLUE LOW CARB ENERGY DEATH NAUSEA, THROAT IRRITATION DEATH Page 1

14 Brand/Product /7/09 MONSTER ENERGY /2/09 JAVA MONSTER PLUS ENERGY ENERGY RUSSIAN FLAVOR BIPOLAR DISORDER, PSYCHOTIC DISORDER, PERSONALITY DISORDER, SUICIDAL IDEATION GASTROENTERITIS SALMONELLA, MALAISE, VOMITING, BACK PAIN, HEADACHE, ABDOMINAL PAIN, COUGH, DIARRHOEA /28/10 MONSTER ENERGY FATIGUE, INFLUENZA LIKE ILLNESS, MEMORY IMPAIRMENT, MIGRAINE, ANGINA PECTORIS, PALPITATIONS, EYE PAIN, MALAISE, DYSURIA, NEUROPATHY PERIPHERAL, NIGHT SWEATS, DECREASED APPETITE, ASTHENIA, PAIN, INSOMNIA, HEADACHE, FLUSHING, VISUAL ACUITY REDUCED LIFE THREATENING, /5/10 MONSTER ENERGY DYSPNOEA, POLLAKIURIA, BLOOD POTASSIUM DECREASED VISITED AN ER, ^ 11/12/10 MONSTER NITROUS DEATH DEATH 6/21/ /8/10 JAVA MONSTER MEAN BEAN COFFEE FLAVORED ENERGY VOMITING, ABDOMINAL PAIN /1/11 MONSTER ENERGY LETHARGY, ABDOMINAL PAIN, HEART RATE ABNORMAL /1/11 MONSTER/LOW CARB ENERGY /14/11 MONSTER HIT MAN ENERGY CONJUNCTIVITIS NAUSEA, DIZZINESS, VOMITING, HEART RATE ABNORMAL, BLOOD PRESSURE FLUCTUATION VISITED A HEALTH CARE PROVIDER, Page 2

15 Brand/Product /26/11 MONSTER MUSCLE SPASMS, ABASIA, DIZZINESS, MUSCULOSKELETAL STIFFNESS, DYSPNOEA, PAIN IN EXTREMITY OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /10/11 MONSTER ENERGY HEART RATE ABNORMAL, SKIN DISCOLOURATION, BLOOD PRESSURE INCREASED VISITED AN ER ^ 12/7/11 MONSTER S LOSS OF CONSCIOUSNESS DEATH 3/27/12 4/4/ /6/11 MONSTER ENERGY HEART RATE IRREGULAR, DYSPNOEA, ATRIAL FIBRILLATION /30/11 MONSTER DEATH DEATH /5/11 MONSTER ENERGY ABDOMINAL PAIN /3/12 MONSTER ENERGY FATIGUE, IRRITABILITY, DEPENDENCE /6/12 MONSTER TREMOR, RESPIRATORY RATE INCREASED VISITED A HEALTH CARE PROVIDER, *150942^ 3/27/12 MONSTER ENERGY 4/9/12 CARDIAC ARREST, ARRHYTHMIA, DRUG TOXICITY DEATH /9/12 MONSTER ENERGY S /27/12 MONSTER ENERGY REHAB PROTEAN + ENERGY 15.5 OZ DYSPNOEA, CHEST PAIN THROAT TIGHTNESS, HYPERSENSITIVITY /15/12 MONSTER ENERGY DIARRHOEA, VOMITING, CHROMATURIA, JAUNDICE, PRURITUS, ANOREXIA, BILIARY SPHINCTEROTOMY, CHOLESTASIS, GALLBLADDER DISORDER, PANCREATIC DISORDER VISITED AN ER, OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), Page 3

16 Brand/Product /31/12 MONSTER ENERGY REHAB PROTEAN RESPIRATORY ARREST, CARDIAC ARREST /11/12 MONSTER ENERGY 16 OZ /29/12 MONSTER ENERGY IMPORT DUB EDITION /20/12 MONSTER ENERGY IMPORT DIZZINESS, TREMOR, ANXIETY OROPHARYNGEAL SWELLING CONFUSIONAL STATE, CHEST PAIN, PAIN, HEADACHE, CHILLS, DIZZINESS VISITED AN ER, VISITED AN ER, /7/12 MONSTER ENERGY 16 OZ DYSPNOEA, FEELING JITTERY, HYPOAESTHESIA /8/12 MONSTER ENERGY HYPERSENSITIVITY, EMOTIONAL DISTRESS, URTICARIA /10/12 MONSTER ENERGY HYPERSENSITIVITY, MALAISE /22/12 MONSTER ENERGY HEART RATE INCREASED, PALPITATIONS, FALL VISITED AN ER, CONGENITAL ANOMALY, REQ. INTERVENTION TO PRVNT PERM. IMPRMNT., LIFE THREATENING, DISABILITY /27/12 MONSTER ENERGY ANTI- GRAVITY 12 FL. OZ ORAL HERPES, HYPERSENSITIVITY, RASH, PRURITUS /30/12 MONSTER ENERGY ABSOLUTELY ZERO ABDOMINAL PAIN UPPER, VOMITING, SYNCOPE, DIARRHOEA, DEHYDRATION /20/12 MONSTER ENERGY CHOKING, HAEMORRHAGE, FOREIGN BODY TRAUMA, RETCHING VISITED AN ER, /11/12 MONSTER ENERGY REHAB GREEN TEA 15.5OZ SYNCOPE, MYOCARDIAL INFARCTION, FOOD POISONING, DIZZINESS, FEELING ABNORMAL VISITED A HEALTH CARE PROVIDER 40 Page 4

17 CAERS Adverse Events Reports Allegedly Related to Rockstar Search Terms: Rockstar, Rock Star The Center for Food Safety Adverse Event Reporting System (CAERS) is a post-market surveillance system that collects reports about events or problems that are allegedly related to CFSAN regulated products. In some reports, information in the reports cannot be verified for accuracy. Furthermore, in many reports, individuals may have used other products, and many products contain multiple ingredients which further complicates the evaluation of adverse event reports. There is no certainty that a reported adverse event can be attributed to a particular product or ingredient. The number of adverse event reports in CAERS received by FDA and the adverse event report itself about a particular product only reflects information AS REPORTED and does not represent any conclusion by FDA regarding a causal relationship or association with the product or ingredient. Due to the continuous inclusion of new or updated information into the CAERS system, reports released from CAERS containing adverse event data may change over time. Each report received by CAERS regarding an individual that experiences an adverse event is assigned a unique report number (Report #). ^ Additional dates indicate receipt of additional materials on report. Report # Brand/Product /3/06 ROCKSTAR ENERGEY /20/06 ROCKSTAR ENERGY FUEL /13/06 DIET ROCKSTAR ENERGY SOFT NAUSEA NAUSEA, HYPERHIDROSIS, HEART RATE INCREASED, OVERDOSE INFLUENZA LIKE ILLNESS, ABDOMINAL DISTENSION, NAUSEA OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /19/07 DIET ROCK STAR HYPERTENSION, BLOOD PRESSURE INCREASED, HEART RATE INCREASED, SUPRAVENTRICULAR TACHYCARDIA DISABILITY, VISITED AN ER, /8/08 ROCKSTAR ENERGY NAUSEA, DIZZINESS, HEADACHE, HEART RATE INCREASED, LOSS OF CONSCIOUSNESS, TACHYCARDIA, IRRITABILITY /9/09 ROCKSTAR ZERO CARB ENERGY /7/09 ROCKSTAR ENERGY VOMITING, CRYING, ANXIETY MANIA, PSYCHOTIC DISORDER, INSOMNIA, BIPOLAR DISORDER VISITED A HEALTH CARE PROVIDER, VISITED AN ER VISITED AN ER, Page 1

18 Brand/Product /1/09 ROCKSTAR ENERGY ARTERIAL DISORDER, INFARCTION, CEREBROVASCULAR ACCIDENT, BIOPSY BLOOD VESSEL ABNORMAL, DISABILITY /13/09 ROCK STAR ROASTED COFFEE AND ENERGY MOCHA AND CREAM COFFEE LACERATION, THROAT IRRITATION VISITED AN ER, VISITED A HEALTH CARE PROVIDER /19/08 ROCKSTAR JUICED ENERGY + GUAVA ENERGY /1/10 ROCKSTAR ENERGY AND POWER SHOT NAUSEA, DIARRHOEA, VOMITING, BURNING SENSATION HEART RATE ABNORMAL, VOMITING, NERVOUSNESS VISITED AN ER /24/10 ROCK STAR ENERGY /13/12 ROCKSTAR INC ROCKSTAR ZERO CARB ZERO SUGAR ABDOMINAL PAIN DYSGEUSIA 13 Page 2

19 U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition CFSAN Adverse Event Reporting System Voluntary Reports on Red Bull Energy Drink January 1, 2004, through October 23, 2012 Introduction FDA s Center for Food Safety and Applied Nutrition (CFSAN) Adverse Event Reporting System (CAERS) collects reports about adverse health events and product complaints related to CFSAN-regulated products, including conventional foods, dietary supplements, and cosmetics. Based on a search of CAERS, this document summarizes the adverse events reported to FDA in connection with products under the label Red Bull between January 1, 2004 and October 23, These products are currently marketed as conventional foods. CAERS includes voluntary reports for cosmetics and conventional foods, and both voluntary and mandatory reports for dietary supplements. Mandatory reports are those required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act. Specifically, dietary supplement manufacturers, packers, and distributors must notify FDA if they receive reports about serious adverse events in connection with the use of their products. This law defines a serious adverse event as an adverse health-related event that is associated with the use of a dietary supplement and that results in death, a lifethreatening experience, inpatient hospitalization, a persistent or significant disability or incapacity, a congenital anomaly or birth defect, or that requires, based on reasonable medical judgment, a medical or surgical intervention to prevent one of those outcomes. The requirement to report serious adverse events to FDA applies only to dietary supplements and not to beverages, other conventional foods, or cosmetics. FDA encourages consumers and health care providers to report adverse events they believe may be related to FDA-regulated products to FDA's MedWatch Adverse Event Reporting Program ( FDA advises consumers to talk with their health care providers before using any product marketed as an energy shot or energy drink. Things You Should Know About Adverse Event Report Data Individual adverse event reports about a particular product and the total number of adverse event reports for that product in CAERS only reflect information AS REPORTED and do not represent any conclusion by FDA about whether the product actually caused the adverse events. Because CAERS is constantly updated with new

20 information, the number of reports for a given product and the content of individual reports may change over time. Even with mandatory reporting of serious adverse events for dietary supplements, generally only a small fraction of adverse events associated with any product is reported. On the other hand, there may be duplicate reports in CAERS for the same adverse event because multiple people (such as an injured consumer and a health care provider who treated him or her) may have submitted reports. There are important limitations to making inferences based on data from adverse event reports, such as those in CAERS. Reports to FDA do not necessarily include all relevant data, such as whether an individual also suffered from other medical conditions (such as cardiac disease) or took other supplements or medication at the same time. Reports may not include accurate or complete contact information for FDA to seek further information about the event, or complainants may choose not to participate in the follow-up investigation. When important information is missing from a report, it is difficult for FDA to fully evaluate whether the product caused the adverse event or simply coincided with it. The fact that an adverse event happened after a person has consumed a product does not necessarily mean that product caused the adverse event.

21 CAERS Adverse Events Reports Allegedly Related to Red Bull Search Terms: Red Bull, Redbull The Center for Food Safety Adverse Event Reporting System (CAERS) is a post-market surveillance system that collects reports about events or problems that are allegedly related to CFSAN regulated products. In some reports, information in the reports cannot be verified for accuracy. Furthermore, in many reports, individuals may have used other products, and many products contain multiple ingredients which further complicates the evaluation of adverse event reports. There is no certainty that a reported adverse event can be attributed to a particular product or ingredient. The number of adverse event reports in CAERS received by FDA and the adverse event report itself about a particular product only reflects information AS REPORTED and does not represent any conclusion by FDA regarding a causal relationship or association with the product or ingredient. Due to the continuous inclusion of new or updated information into the CAERS system, reports released from CAERS containing adverse event data may change over time. Each report received by CAERS regarding an individual that experiences an adverse event is assigned a unique report number (Report #). ^Additional dates indicate receipt of additional materials on report. Report # Brand/Product /29/04 REDBULL ADVERSE DRUG REACTION, PANCREATITIS /10/05 RED BULL HIGH ENERGY FATIGUE /4/05 RED BULL PANIC ATTACK, ANXIETY, VISION BLURRED, DIZZINESS, DECREASED APPETITE, FATIGUE, ADRENAL INSUFFICIENCY, INSOMNIA, CONFUSIONAL STATE, DISTURBANCE IN ATTENTION, PHYSICAL EXAMINATION, DEPENDENCE VISITED A HEALTH CARE PROVIDER VISITED A HEALTH CARE PROVIDER /20/06 RED BULL ENERGY NAUSEA, HYPERHIDROSIS, HEART RATE INCREASED, OVERDOSE OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /22/07 RED BULL CHEST PAIN, DYSPNOEA, DIZZINESS, BLOOD PRESSURE INCREASED, HEART RATE INCREASED VISITED AN ER, LIFE THREATENING /10/07 RED BULL ACUTE MYOCARDIAL INFARCTION, INTRACARDIAC THROMBUS VISITED A HEALTH CARE PROVIDER, LIFE THREATENING Page 1

22 Brand/Product /31/07 SUGAR FREE RED BULL VISION BLURRED, NECK PAIN, PANIC ATTACK, ELECTROCARDIOGRAM, HEART RATE IRREGULAR, ANXIETY, DEPRESSED LEVEL OF CONSCIOUSNESS, SENSORY LOSS,, VISITED A HEALTH CARE PROVIDER /1/08 RED BULL FLUSHING, TREMOR, TACHYCARDIA, LIVEDO RETICULARIS VISITED AN ER, /3/08 RED BULL VERTIGO, BLINDNESS, VOMITING, NAUSEA OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /2/08 RED BULL CHEST PAIN, BLOOD PRESSURE FLUCTUATION, DIARRHOEA, ABDOMINAL PAIN, FAECES DISCOLOURED, GLOSSODYNIA, HYPERSENSITIVITY VISITED A HEALTH CARE PROVIDER, VISITED AN ER /29/09 RED BULL ENERGY /29/10 RED BULL ENERGY /31/10 RED BULL ENERGY /2/11 RED BULL ENERGY ANXIETY, AGGRESSION MENTAL IMPAIRMENT, DYSARTHRIA, DYSPHONIA VOMITING CONVULSION VISITED AN ER OTHER SERIOUS (IMPORTANT MEDICAL EVENTS), /6/11 RED BULL/RED BULL SUGAR FREE VOMITING /22/11 RED BULL ENERGY HEART RATE ABNORMAL, ABDOMINAL PAIN, FEELING JITTERY, ANXIETY, DYSPEPSIA, ABDOMINAL PAIN, HEART RATE INCREASED /1/11 RED BULL LETHARGY, ABDOMINAL PAIN, HEART RATE ABNORMAL Page 2

23 Brand/Product /10/11 RED BULL ENERGY HEART RATE ABNORMAL, SKIN DISCOLOURATION, BLOOD PRESSURE INCREASED VISITED AN ER /29/12 RED BULL SYNCOPE, DEHYDRATION OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) /20/12 RED BULL ENERGY SYNCOPE, BLOOD PRESSURE FLUCTUATION /4/12 REDBULL CARDIAC DISORDER OTHER SERIOUS (IMPORTANT MEDICAL EVENTS) 21 Page 3

FOI CAERS Reports Allegedly Related to Multiple Energy Drinks

FOI CAERS Reports Allegedly Related to Multiple Energy Drinks FOI 14-17 Reports Allegedly Related to Multiple Energy Drinks Search Terms: Products Listed FDA s Center for Food Safety and Applied Nutrition s (CFSAN s) Adverse Event Reporting System () is a post-market

More information

Database of Adverse Event Notifications - medicines

Database of Adverse Event Notifications - medicines Database of Adverse Event Notifications - medicines You searched for the following 3 medicines between 01/01/2017 01/01/2018: Ferinject 100mg/2mL (Ferric carboxymaltose) Ferinject 500mg/10mL (Ferric carboxymaltose)

More information

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014

Case Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014 - 16Oct2014 Report Run Date: 20-Oct-2014 Data Lock Date: 16-Oct-2014 19:00:06 Earliest Reaction Date: 28-Oct-2009 MedDRA Version: MedDRA 17.0 Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine : Alle cases

More information

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015

Summary details of suspected adverse reactions/events associated with the use of Gardasil 1st March st March 2015 Page 1 of 6 Adverse (s) Date Outcome 2014-019844 04/03/2014 13 Years Prophylaxis GARDASIL 04/12/2013 Nausea 04/12/2013 06/12/2013 Headache 04/12/2013 06/12/2013 Vomiting 04/12/2013 06/12/2013 Asthenia

More information

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine

Suspected Adverse Reaction Analysis. CERVARIX Human papillomavirus (HPV) vaccine Suspected Adverse Reaction Analysis CERVARIX Human papillomavirus (HPV) vaccine 2 May 2009 This report summarises the adverse reactions suspected to have been caused by Cervarix human papillomavirus (HPV)

More information

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations.

MEDICINE SUMMARY. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES. Tachycardia. Supraventricular tachycardia. Palpitations. Atomoxetine Hydrochloride Layer 1 of 8 ALL REPORT DATES Causality Unclear Exclud Total Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic

More information

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015

Summary listing of suspected adverse reactions and events associated with use of Gardasil 01/06/ /12/2015 1 2015-023780 2015-023788 2015-023805 2015-023819 2015-023820 2015-023821 Injection site swelling Transient immobility Abdominal pain Visual acuity reduced Chronic fatigue syndrome Mental disorder Pallor

More information

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber. Know Your Medicines Duloxetine The purpose of this leaflet is to give you some general information on duloxetine, and is intended as a guide only. This should be read in conjunction with the official patient

More information

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines

Adverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines Adverse events following immunisation (AEFI) with 00/0 seasonal influenza vaccines Netherlands Pharmacovigilance Centre Lareb 8 juli 0 Goudsbloemvallei 7 57 MH s-hertogenbosch www.lareb.nl info@lareb.nl

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR: Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including:

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including: Medication Guide VENLAFAXINE XR (venlafaxine hydrochloride) (Extended-Release Capsules) Read the Medication Guide that comes with venlafaxine hydrochloride extended-release before you start taking it and

More information

MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia.

MEDICINE SUMMARY. CHLORPROMAZINE HYDROCHLORIDE Layer 1 of 1 ALL REPORT DATES. Febrile neutropenia. Lymphadenopathy. Thrombocythaemia. ALL REPORT DATES Causality Unclear Excluded Total Death Outcome Sole Suspected - Cases Including Medicine - Occurrences of Medicine - Reactions Related to Medicine Blood and lymphatic system disorders

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER 250 mg film-coated tablets. 500 mg film-coated tablets. 750 mg film-coated tablets. 1000 mg film-coated tablets. Levetiracetam

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

Medication Guide Fluoxetine Oral Solution USP What is the most important information I should know about fluoxetine oral solution?

Medication Guide Fluoxetine Oral Solution USP What is the most important information I should know about fluoxetine oral solution? Medication Guide Fluoxetine Oral Solution USP Read the Medication Guide that comes with fluoxetine before you start taking it and each time you get a refill. There may be new information. This Medication

More information

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE

GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE The CSM Working Group on Patient Information recognises that users may not be familiar with the terms used in patient information leaflets to describe unwanted

More information

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine

More information

Karl McManus Foundation Representing the Australian Lyme Disease Community Symptoms Monitoring Chart

Karl McManus Foundation Representing the Australian Lyme Disease Community Symptoms Monitoring Chart Name Diagnosis Date Pathogens Present Date GENERAL Fever Chills Night sweats Fatigue Poor Stamina Weight Loss/Gain Gernalised Pain Migratory Pain Shooting Pain Daytime Napping Menstrual Irregularity Milk

More information

Medicine summary - Antipsychotics- chlorpromazine

Medicine summary - Antipsychotics- chlorpromazine 591 21 241 Blood and lymphatic system disorders Anaemia 3 0 0 Aplastic anaemia 3 1 0 Pancytopenia 2 1 1 Thrombocytopenia 6 1 1 Thrombocytosis 1 0 0 Lymphadenopathy 3 1 1 Eosinophilia 5 0 0 Leukocytosis

More information

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013 CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Block GA, Bushinsky DA, Cunningham J, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism:

More information

Headache Follow-up Visit Form

Headache Follow-up Visit Form !1 Headache Follow-up Visit Form We will be unable to see you unless this form is completely filled out. We appreciate your thoroughness. Name DOB Age Today s Date Referring doctor: Primary doctor: Neurologist:

More information

Continence PGD - Oxybutynin 5mg Modified Release

Continence PGD - Oxybutynin 5mg Modified Release Continence PGD - Oxybutynin 5mg Modified Release Patient group direction for the supply of Oxybutynin Lyrinel XL 5mg and 10mg tablets, maximum dose of 20mg/day to patients suffering from urinary frequency,

More information

Initial Consultation

Initial Consultation Today s Date: Initial Consultation Thank you for choosing Apollo Health and Wellness. Please take your time to fill out this form. It will help us to concentrate on areas of your health that need attention

More information

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental use by a child is a medical emergency

More information

Caspian Acupuncture -- Health History Form Anita Tayyebi EAMP, LAc. 652 SW 150 th St Burien WA 98166

Caspian Acupuncture -- Health History Form Anita Tayyebi EAMP, LAc. 652 SW 150 th St Burien WA 98166 Frist Name Last: Date Phone (H) (C) (W) E-mail Address City State Zip Age DOB Place of Birth _ Marital/Partnership Status Preferred Gender Pronoun _ Profession Family Physician Telephone # Referred By

More information

Medication Guide SARAFEM (SAIR-a-fem) (fluoxetine hydrochloride) Tablets

Medication Guide SARAFEM (SAIR-a-fem) (fluoxetine hydrochloride) Tablets Medication Guide SARAFEM (SAIR-a-fem) (fluoxetine hydrochloride) Tablets Read the Medication Guide that comes with SARAFEM before you start taking it and each time you get a refill. There may be new information.

More information

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride Package leaflet: Information for the patient Cetirizin Sandoz 10 mg film-coated tablets cetirizine dihydrochloride [For medicine available only on prescription:] Read all of this leaflet carefully before

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, 0.5 mg AT/H/PSUR/0028/001 Date of FAR: Core Safety Profile Active substance: Anagrelide hydrochloride Pharmaceutical form(s)/strength: Capsules, 0.5 mg P-RMS: AT/H/PSUR/0028/001 Date of FAR: 02.08.2010 4.3 Contraindications Hypersensitivity

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg NL/H/PSUR/0002/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg NL/H/PSUR/0002/001 Date of FAR: Core Safety Profile Active substance: Rizatriptan Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg P RMS: NL/H/PSUR/0002/001 Date of FAR: 23.05.2011 4.3 Contraindications

More information

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1 Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma

More information

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring

Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring Lessons learnt from Influenza A(H1N1) vaccines benefit-risk monitoring ENCePP Plenary meeting Xavier Kurz 8 June 20 An agency of the European Union Contents 1. Safety database at time of authorisation

More information

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: 0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology

More information

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.)

Please list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.) Date: Patient Name: D.O.B Last First M.I History of Present Illness: What is the reason for your visit? Date symptom started? Please list any treatments you have previously had for current illness. (Physical

More information

Bridges Family Wellness PC. New Patient Intake. Bridges Family Wellness Intake Form SE Lake Rd, Suite 102 Milwaukie, OR

Bridges Family Wellness PC. New Patient Intake. Bridges Family Wellness Intake Form SE Lake Rd, Suite 102 Milwaukie, OR New Patient Intake Bridges Family Wellness Intake Form Full Name: * What is your birthdate? MM/DD/YYYY * What is your gender identity? * Home address: * Cell Phone * Other Phone number(s): Emergency Contact

More information

Nilotinib AEs (adverse events) in CML population:

Nilotinib AEs (adverse events) in CML population: Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR: Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension

More information

MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets

MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets FDA-Approved Medication Guide MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets Savella is not used to treat depression, but it acts like medicines that are used to treat depression (antidepressants)

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR: Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications

More information

Share the important information in this Medication Guide with members of your household.

Share the important information in this Medication Guide with members of your household. Medication Guide BUPRENORPHINE (BUE-pre-NOR-feen) and NALOXONE (nal-ox-one) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine and naloxone sublingual tablets in a secure place away from children.

More information

Patient Information. Marital Status (Single, Married, Life Partner, Divorced, Widowed) CHIEF COMPLAINT

Patient Information. Marital Status (Single, Married, Life Partner, Divorced, Widowed) CHIEF COMPLAINT Patient Information Name Date Home Address City State Zip Phone E-mail Address Cell Phone: Business Address City State Zip Phone Occupation Place of Birth Date of Birth Age Height Weight Soc. Sec. # Sex

More information

Product Information FLUORESCEIN SERB 500mg/5mL

Product Information FLUORESCEIN SERB 500mg/5mL Product Information FLUORESCEIN SERB 500mg/5mL (fluorescein sodium) NAME OF THE MEDICINE Active ingredient: Chemical name: fluorescein sodium disodium 2-(3-oxo-6-oxido-3H-xanthen-9-yl)benzoate Molecular

More information

Package leaflet: Information for the user. Pregabalin Kern Pharma 75 mg hard capsules

Package leaflet: Information for the user. Pregabalin Kern Pharma 75 mg hard capsules Package leaflet: Information for the user Pregabalin Kern Pharma 75 mg hard capsules Read all of this leaflet carefully before you start taking this medicine because it contains important information for

More information

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425) IDENTIFYING INFORMATION PATIENT INFORMATION FORM Patient's Name: DOB: Ethnicity/race: Gender: Primary language if other than English: Address: Phone: Home/ Mobile/ Work Email: Occupation: Marital Status:

More information

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place

More information

Package Leaflet: Information for the user. Pregabalin 1A Farma 225 mg hard capsules, Pregabalin 1A Farma 300 mg hard capsules.

Package Leaflet: Information for the user. Pregabalin 1A Farma 225 mg hard capsules, Pregabalin 1A Farma 300 mg hard capsules. Package Leaflet: Information for the user Pregabalin 1A Farma 25 mg hard capsules, Pregabalin 1A Farma 50 mg hard capsules, Pregabalin 1A Farma 75 mg hard capsules, Pregabalin 1A Farma 100 mg hard capsules,

More information

Medicine summary - Antipsychotics- haloperidol

Medicine summary - Antipsychotics- haloperidol 748 22 330 Blood and lymphatic system disorders Anaemia 2 0 0 Bone marrow failure 1 0 0 Pancytopenia 4 0 1 Haemolytic anaemia 1 0 0 Thrombocytopenia 2 0 0 Lymphadenopathy 1 0 0 Splenomegaly 2 0 0 Eosinophilia

More information

Treatment of Alzheimer s disease

Treatment of Alzheimer s disease NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Treatment of Alzheimer s disease Acetylcholinesterase

More information

CENTRAL CARE POLICY SYMPTOMS OF ILLNESS. Policy: Consumers will be observed for symptoms of physical problems, distress, pain, or unusual behaviors.

CENTRAL CARE POLICY SYMPTOMS OF ILLNESS. Policy: Consumers will be observed for symptoms of physical problems, distress, pain, or unusual behaviors. Page 1 of 5 CENTRAL CARE POLICY SYMPTOMS OF ILLNESS SUBJECT: SYMPTOMS OF ILLNESS ANNUAL REVIEW MONTH: June RESPONSIBLE FOR REVIEW: Director of Central Care LAST REVISION DATE: June 2009 Policy: Consumers

More information

Nursing Process Focus: Patients Receiving Dextran 40 (Gentran 40)

Nursing Process Focus: Patients Receiving Dextran 40 (Gentran 40) Assess for presence/history of hypovolemia, shock, venous thrombosis. Assess vital signs: Hypovolemic shock secondary to surgery, burns, hemorrhage, other serious condition PT and PTT abnormalities Venous

More information

Package leaflet: information for the user. MILDRONĀTS 0.5 g/5 ml solution for injection. Meldonium dihydricum

Package leaflet: information for the user. MILDRONĀTS 0.5 g/5 ml solution for injection. Meldonium dihydricum Package leaflet: information for the user MILDRONĀTS 0.5 g/5 ml solution for injection Meldonium dihydricum Read all of this leaflet carefully before you start using this medicine because it contains important

More information

Providence Medical Group

Providence Medical Group Providence Medical Group To our valued patients: In order to provide you with our full attention when you come for an appointment, we would like to ask you to be aware of the following guidelines. Insurance

More information

PATIENT INFORMATION LEAFLET AMLOC RANGE

PATIENT INFORMATION LEAFLET AMLOC RANGE SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: AMLOC 5 mg tablets AMLOC 10 mg tablet Read all of this leaflet carefully before you start taking AMLOC. Keep this leaflet. You may need to read it

More information

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII)

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII) MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental

More information

Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension

Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Read this Patient Information before you start taking VERSACLOZ and each time you get a refill. There may be new information. This

More information

FDA APPROVED MEDICATION GUIDE

FDA APPROVED MEDICATION GUIDE FDA APPROVED MEDICATION GUIDE Valproic Acid Oral Solution Read this Medication Guide before you start taking valproic acid and each time you get a refill. There may be new information. This information

More information

Cardiovascular and Respiratory Disorders

Cardiovascular and Respiratory Disorders Cardiovascular and Respiratory Disorders Blood Pressure Normal blood pressure is 120/80 mmhg (millimeters of mercury) Hypertension is when the resting blood pressure is too high Systolic BP is 140 mmhg

More information

WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS

WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS WELCOME TO THE NORTHSHORE UNIVERSITY HEALTHSYSTEM SLEEP CENTERS Prior to your office visit, we request that you complete this questionnaire. It asks questions not only about your sleeping habits and behavior

More information

4.4 Special warnings and precautions for use

4.4 Special warnings and precautions for use SUMMARY OF PRODUCT CHARACTERISTICS 4.3 Contraindications Durogesic is contraindicated in patients with known hypersensitivity to fentanyl or to the excipients present in the patch. Acute or postoperative

More information

HAMILTON ANXIETY RATING SCALE (HAM-A)

HAMILTON ANXIETY RATING SCALE (HAM-A) HAMILTON ANXIETY RATING SCALE (HAM-A) Mood Disorders Psychopharmacology Unit www.mdpu.ca 1 Patient Information Patient Date Day Mth. Year Time Hour Min Personal notes 1. Anxious mood This item covers the

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient

More information

Package leaflet: Information for the user. Sumatriptan Amneal 100 mg tablets. sumatriptan

Package leaflet: Information for the user. Sumatriptan Amneal 100 mg tablets. sumatriptan Package leaflet: Information for the user Sumatriptan Amneal 50 mg tablets Sumatriptan Amneal 100 mg tablets sumatriptan Read all of this leaflet carefully before you start taking this medicine because

More information

1.Suicidal thoughts or actions:

1.Suicidal thoughts or actions: Medication Guide FLUOXETINE (Floa-OX-e-teen) TABLETS, USP Read the Medication Guide that comes with fluoxetine tablets before you start taking it and each time you get a refill. There may be new information.

More information

Guide for Patients & Caregivers

Guide for Patients & Caregivers Pr ALERTEC * Modafinil Tablets 100 mg Central Nervous System Stimulant Guide for Patients & Caregivers ALERTEC is manufactured by: Teva Canada Limited Toronto, Ontario M1B 2K9 ALERTEC is distributed by:

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr BACLOFEN Baclofen Tablets 10 mg and 20 mg This leaflet is part III of a three-part "Product Monograph" published when BACLOFEN was approved for sale in Canada and is designed

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give

More information

Broward Oncology Associates, P.A. PATIENT INFORMATION

Broward Oncology Associates, P.A. PATIENT INFORMATION NAME: BIRTHDATE: AGE: LOCAL ADDRESS (Street city state zip): HOME TELEPHONE# CELL # SOCIAL SECURITY #: - - SEX MARITAL STATUS WHAT IS YOUR HT? WHAT IS YOUR WT? EMPLOYER WORK# SPOUSE'S NAME SPOUSE'S EMPLOYER

More information

MEDICATION GUIDE Valproic Acid (val pro ic acid) Capsules

MEDICATION GUIDE Valproic Acid (val pro ic acid) Capsules MEDICATION GUIDE Valproic Acid (val pro ic acid) Capsules Read this Medication Guide before you start taking Valproic Acid Capsules and each time you get a refill. There may be new information. This information

More information

(levomilnacipran) extended-release capsules

(levomilnacipran) extended-release capsules MEDICATION GUIDE FETZIMA (fet-zee-muh) (levomilnacipran) extended-release capsules Read this Medication Guide before you start taking FETZIMA and each time you get a refill. There may be new information.

More information

Sound View Acupuncture and Chinese Herbs 5410 California Ave SW, #202, Seattle, WA

Sound View Acupuncture and Chinese Herbs 5410 California Ave SW, #202, Seattle, WA Sound View Acupuncture and Chinese Herbs 5410 California Ave SW, #202, Seattle, WA 98136 206.200.3595 Today s date Name Legal name (if different) Phone (primary) (secondary) Address City State Zip Email

More information

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET PPM Code: E1981 PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S2 PROPRIETARY NAME DOSAGE FORM: film coated tablets Read all of this leaflet carefully because it contains important information for you.

More information

Public Case Detail. Case Number : Reaction : Medicine details : Cases Count: 15. Gender : Weight (kg) : 36Y. Hospitalisation : Age :

Public Case Detail. Case Number : Reaction : Medicine details : Cases Count: 15. Gender : Weight (kg) : 36Y. Hospitalisation : Age : Case Number : 231711 9/8/27 M 36Y Unknown Urticaria Reason : Tablet 4 Milligram 2 times Oral CITALOPRAM HYDROBROMIDE (Other drug) Reason : 4 Milligram Oral PUTRAN2 Page 1 of 18 Case Number : 233954 M 3/1/27

More information

Joseph S. Weiner, MD, PC Patient History Form

Joseph S. Weiner, MD, PC Patient History Form Date: / / NAME: Last First M. I. Age: Sex: q F q M Birthdate: / / What specific questions or goals do you have for this appointment? Please list the names of other clinicians you have seen for this problem:

More information

Continence PGD transdermal oxybutynin Kentera patch 36mg

Continence PGD transdermal oxybutynin Kentera patch 36mg Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence

More information

Package leaflet: Information for the user. Alzain 225 mg Capsules, Hard. Alzain 150 mg Capsules, Hard. Alzain 300 mg Capsules, Hard.

Package leaflet: Information for the user. Alzain 225 mg Capsules, Hard. Alzain 150 mg Capsules, Hard. Alzain 300 mg Capsules, Hard. Package leaflet: Information for the user Alzain 25 mg Capsules, Hard Alzain 50 mg Capsules, Hard Alzain 75 mg Capsules, Hard Alzain 100 mg Capsules, Hard Alzain 150 mg Capsules, Hard Alzain 200 mg Capsules,

More information

Circulation and Cardiac Emergencies. Emergency Medical Response

Circulation and Cardiac Emergencies. Emergency Medical Response Circulation and Cardiac Emergencies Lesson 19: The Circulatory System and Cardiac Emergencies You Are the Emergency Medical Responder You are called to the home of a 50-year-old man whose wife called 9-1-1

More information

VACCINE-RELATED ALLERGIC REACTIONS

VACCINE-RELATED ALLERGIC REACTIONS VACCINE-RELATED ALLERGIC REACTIONS Management of Anaphylaxis Public Health Immunization Program June 2018 VACCINE-RELATED ADVERSE EVENTS Local reactions pain, edema, erythema Systemic reactions fever,

More information

Package leaflet: information for the user Nicorette Microtab 2 mg sublingual tablets. Nicotine

Package leaflet: information for the user Nicorette Microtab 2 mg sublingual tablets. Nicotine Nicorette Microtab for packaging containing blister Package leaflet: information for the user Nicorette Microtab 2 mg sublingual tablets Nicotine Read all of this leaflet carefully before you start using

More information

Syncope and Seizure Questionnaire

Syncope and Seizure Questionnaire Syncope and Seizure Questionnaire World College of Neurology 2/79 Wheatley Drive Bull Creek WA 6149 T 08 93320488 F 08 93329988 Copyright 2011. All rights reserved. Patient Name: MAIN PROBLEM I am here

More information

New Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests:

New Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests: New Patient History Name: DOB: Sex: Date: Chief Complaint: 1. Give a brief description of the problem you are seeking treatment for today: 2. Have you been evaluated for this problem or had any tests for

More information

Package Leaflet: Information For The User. Pregabalin Accord 75 mg hard capsules, Pregabalin Accord 150 mg hard capsules,

Package Leaflet: Information For The User. Pregabalin Accord 75 mg hard capsules, Pregabalin Accord 150 mg hard capsules, Package Leaflet: Information For The User Pregabalin Accord 25 mg hard capsules, Pregabalin Accord 50 mg hard capsules, Pregabalin Accord 75 mg hard capsules, Pregabalin Accord 100 mg hard capsules, Pregabalin

More information

Name: Date of birth: Address: City: State: Zip: Phone: (day) (evening): (cell): address: Occupation: Who referred you/how did you hear about us?

Name: Date of birth: Address: City: State: Zip: Phone: (day) (evening): (cell):  address: Occupation: Who referred you/how did you hear about us? Name: Date of birth: Address: City: State: Zip: Phone: (day) (evening): (cell): Email address: Occupation: Who referred you/how did you hear about us? Your primary health care provider: Phone: Emergency

More information

New Patient Sleep Intake

New Patient Sleep Intake New Patient Sleep Intake Name: Date of Birth: Primary Care Physician: Date of Visit: Referring Physician and/or Other Physicians: Retail Pharmacy: Mail Order Pharmacy: Address: Mail Order Phone #: Phone

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Clostridium botulinum neurotoxin type A haemagglutinin complex Pharmaceutical form(s)/strength: powder for solution for injection, 300 unit and 500 unit P-RMS:

More information

Package leaflet: Information for the user. Pregabalin Zentiva 225 mg hard capsules. Pregabalin Zentiva 150 mg hard capsules

Package leaflet: Information for the user. Pregabalin Zentiva 225 mg hard capsules. Pregabalin Zentiva 150 mg hard capsules Package leaflet: Information for the user Pregabalin Zentiva 25 mg hard capsules Pregabalin Zentiva 50 mg hard capsules Pregabalin Zentiva 75 mg hard capsules Pregabalin Zentiva 100 mg hard capsules Pregabalin

More information

Heart Disorders. Cardiovascular Disorders (Part B-1) Module 5 -Chapter 8. Overview Heart Disorders Vascular Disorders

Heart Disorders. Cardiovascular Disorders (Part B-1) Module 5 -Chapter 8. Overview Heart Disorders Vascular Disorders Cardiovascular Disorders (Part B-1) Module 5 -Chapter 8 Overview Heart Disorders Vascular Disorders Susie Turner, MD 1/7/13 Heart Disorders Coronary Artery Disease Cardiac Arrhythmias Congestive Heart

More information

Complete the CE Checklist for Customized Symptoms. Page 1 of 6

Complete the CE Checklist for Customized Symptoms. Page 1 of 6 Progress Tracking Complete the CE Checklist for Customized Symptoms Page 1 of 6 Generic Positive Symptom Tracking Concentration Quality Of Sleep Motivation/Energy Patience Short Term Memory Appetite Positive

More information

Cetirizine Proposed Core Safety Profile

Cetirizine Proposed Core Safety Profile Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function

More information

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash -

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash - Review of Systems: 0-1 year old Constitution neg Eyes neg GI neg Neurological neg + Activity Change - + Eye Discharge - + Reflux - + Facial Asymmetry - + Appetite Change - + Eye Redness - + Vomiting -

More information

New Patient Medical History Intake Form

New Patient Medical History Intake Form New Patient Medical History Intake Form Name: Todays Date: / / Date of Birth: / / Age: Gender: M / F Marital Status: S M D W Address: City: State: Zip Code Primary Ph.# (cell, hm, wk) Email Address 2nd

More information

MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets

MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets Read this Medication Guide carefully before you start using WELLBUTRIN and each time you get a refill. There may be new information.

More information

Medication Guide REMERONSolTab (rĕm' - ĕ - rŏn - sŏl' tăb) (mirtazapine) Orally Disintegrating Tablets

Medication Guide REMERONSolTab (rĕm' - ĕ - rŏn - sŏl' tăb) (mirtazapine) Orally Disintegrating Tablets Medication Guide REMERONSolTab (rĕm' - ĕ - rŏn - sŏl' tăb) (mirtazapine) Orally Disintegrating Tablets Read the Medication Guide that comes with REMERONSolTab before you start taking it and each time you

More information

Case Series Drug Analysis Print Name: Isotretinoin

Case Series Drug Analysis Print Name: Isotretinoin Report Run Date: 30-Dec-2013 Data Lock Date: 27-Dec-2013 23:09:23 Earliest Reaction Date: 12-Jun-1997 MedDRA Version: MedDRA 16.1 Isotretinoin: No description provided. Report Run Date: 30-Dec-2013, Page

More information

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care

New Patient Form. Patient Demographics. Emergency Information. Employment Information. Page 1 of 7. Family Health Chiropractic Care Page 1 of 7 Patient Demographics First Name* Last Name* Date Of Birth* Home Phone* Mobile Phone Phone Gender* Email Preferred Communication Street Address 1* Street Addresss 2 Zip* City* State* Emergency

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR: Core Safety Profile Active substance: Bisoprolol Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg P - RMS: FI/H/PSUR/0002/002 Date of FAR: 13.12.2011

More information

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Effexor XR /

More information